Literature DB >> 16201596

[Clostridium difficile ribotype 027, toxinotype III in The Netherlands].

E J Kuijper1, S B Debast, E Van Kregten, N Vaessen, D W Notermans, P J van den Broek.   

Abstract

Recently, two Dutch hospitals reported outbreaks of Clostridium difficile ribotype 027, toxinotype III. This strain, which was seen earlier in the United States, Canada and the United Kingdom, produces large amounts of toxins due to a defect in the toxin-regulating gene and causes severe diarrhoea. Antibiotic use, especially use of fluoroquinolones, is a risk factor. Control of outbreaks is hampered by the fact that Clostridium forms spores that can survive for a very long time in the environment and are resistant to the usual surface disinfectants. Protocols for diagnostic investigations, prevention and control of outbreaks are available.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16201596

Source DB:  PubMed          Journal:  Ned Tijdschr Geneeskd        ISSN: 0028-2162


  7 in total

1.  Molecular analysis of Clostridium difficile PCR ribotype 027 isolates from Eastern and Western Canada.

Authors:  Duncan R MacCannell; Thomas J Louie; Dan B Gregson; Michel Laverdiere; Annie-Claude Labbe; Felicia Laing; Scott Henwick
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

2.  Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain.

Authors:  François Lamontagne; Annie-Claude Labbé; Olivier Haeck; Olivier Lesur; Mathieu Lalancette; Carlos Patino; Martine Leblanc; Michel Laverdière; Jacques Pépin
Journal:  Ann Surg       Date:  2007-02       Impact factor: 12.969

3.  Comparative phylogenomics of Clostridium difficile reveals clade specificity and microevolution of hypervirulent strains.

Authors:  R A Stabler; D N Gerding; J G Songer; D Drudy; J S Brazier; H T Trinh; A A Witney; J Hinds; B W Wren
Journal:  J Bacteriol       Date:  2006-10       Impact factor: 3.490

4.  Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA).

Authors:  L Clifford McDonald; Dale N Gerding; Stuart Johnson; Johan S Bakken; Karen C Carroll; Susan E Coffin; Erik R Dubberke; Kevin W Garey; Carolyn V Gould; Ciaran Kelly; Vivian Loo; Julia Shaklee Sammons; Thomas J Sandora; Mark H Wilcox
Journal:  Clin Infect Dis       Date:  2018-03-19       Impact factor: 9.079

5.  Clostridium difficile ribotype 027, toxinotype III, the Netherlands.

Authors:  Ed J Kuijper; Renate J van den Berg; Sylvia Debast; Caroline E Visser; Dick Veenendaal; Annet Troelstra; Tjallie van der Kooi; Susan van den Hof; Daan W Notermans
Journal:  Emerg Infect Dis       Date:  2006-05       Impact factor: 6.883

6.  [Emerging multidrug-resistant microorganisms among travelers returning to France and persons repatriated from foreign hospitals].

Authors:  Didier Lepelletier; Antoine Andremont; Patrick Choutet
Journal:  Bull Acad Natl Med       Date:  2009-11       Impact factor: 0.144

7.  Clostridium difficile PCR ribotypes in calves, Canada.

Authors:  Alexander Rodriguez-Palacios; Henry R Stämpfli; Todd Duffield; Andrew S Peregrine; Lise A Trotz-Williams; Luis G Arroyo; Jon S Brazier; J Scott Weese
Journal:  Emerg Infect Dis       Date:  2006-11       Impact factor: 6.883

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.